DelveInsight’s “Colorectal Cancer Market Insight, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of Colorectal Cancer, historical and forecasted epidemiology as well as the Colorectal Cancer market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Unlock detailed insights into the Colorectal Cancer Market by downloading the comprehensive report from DelveInsight @ Colorectal Cancer Therapeutics Market
Key Takeaways from the Colorectal Cancer Market Report
- In January 2026, the FDA accepted the NDA for zanzalintinib in combination with an immune checkpoint inhibitor for metastatic colorectal cancer (mCRC). The filing, supported by Exelixis, targets patients with microsatellite stable (MSS) tumors, a population that historically responds poorly to traditional immunotherapy.
- In 2023, the United States accounted for ~30% of the total incident cases of Colorectal cancer in the 7MM.
- Approximately 68,400 cases of CRC were reported among individuals aged 65-84 years in the United States, in 2023
- In 2023, ~52,000 cases of CRC were localized in the right colon in the United States.
- In 2023, localized CRC accounted for the highest number of cases, as far as stage-specific cases of CRC are concerned in the US.
- Surveillance, Epidemiology, and End Results (SEER), published age and gender data for CRC patients. As per the registry, percentages of cases by stages was segregated as localized, regional, distant and unknown which comprised of 38%, 35%, 22% and 4% respectively.
- The leading Colorectal Cancer Companies such as Shanghai Henlius Biotech, Agenus, Tizona Therapeutics, Surgimab, Novartis, Bexion Pharmaceuticals, Syndax Pharmaceuticals, Exelixis, AbbVie, Tyligand Pharmaceuticals, Bristol Myers Squibb, Eisai, Bold Therapeutics, and others.
- Promising Colorectal Cancer Therapies such as Serplulimab（HLX10) + Bevacizumab + Chemotherapy, Botensilimab ± Balstilimab, TTX-080, SGM-101, HRO761, BXQ-350 + FOLFOX + bevacizumab, Revumenib, Zanzalintinib + atezolizumab vs. regorafenib, Temab-A (ABBV-400), TSN333 and TSN1611, Pumitamig, E7386, BOLD-100 in combination with FOLFOX Chemotherapy, and others.
Gain a competitive edge in the Colorectal Cancer Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Colorectal Cancer Treatment Drugs
Colorectal Cancer Epidemiology Segmentation in the 7MM
- Total Incident Cases of CRC
- Gender-specific Cases of CRC
- Age-specific Cases of CRC
- Tumor Localization-specific Cases of CRC
- Stage-specific Cases of CRC
- Mutation-specific Cases of CRC
- Total Treated Cases of CRC
Download the report to understand which factors are driving Colorectal Cancer Epidemiology Trends @ Colorectal Cancer Prevalence
Marketed Colorectal Cancer Drugs
- FRUZAQLA (fruquintinib): Takeda
FRUZAQLA is a selective oral inhibitor of VEGFR -1, -2 and -3. VEGFR inhibitors play a pivotal role in blocking tumor angiogenesis. FRUZAQLA was designed to have enhanced selectivity that limits off-target kinase activity, allowing for high drug exposure, sustained target inhibition, and flexibility for the potential use as part of combination therapy. FRUZAQLA is the First Targeted Therapy Approved for mCRC regardless of biomarker status or prior types of therapies in more than a decade. In November 2023, Takeda received US FDA approval of FRUZAQLA for previously treating metastatic colorectal cancer.
- TUKSYA (tucatinib): Genentech/Seagen
TUKYSA is an oral medicine that is a tyrosine kinase inhibitor of the HER2 protein, a protein that contributes to cancer cell growth. HER2 is overexpressed in multiple cancers, including colorectal cancers. In preclinical in vitro studies, the drug inhibited phosphorylation of HER2 and HER3, resulting in inhibition of downstream MAPK and AKT signaling and cell growth (proliferation), and showed anti-tumor activity in HER2-expressing tumor cells. The combination of TUKYSA and trastuzumab have also been shown to increase anti-tumor activity in vitro and in vivo compared to either medicine alone.
- ENHERTU (trastuzumab deruxtecan): AstraZeneca and Daiichi Sankyo
In April 2024, AstraZeneca and Daiichi Sankyo’s ENHERTU has received FDA accelerated approval in the US for treating adults with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have exhausted other treatment options. This approval, the first of its kind for a HER2-directed antibody-drug conjugate (ADC) across various tumor types, is based on the objective response rate and duration of response from the DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02 Phase II trials. Continued approval will depend on confirmatory trials demonstrating clinical benefit.
Emerging Colorectal Cancer Drugs
- Favezelimab + pembrolizumab: Merck
Favezelimab is an investigational anti-lymphocyte activation gene-3 (LAG-3) antibody designed to restore T cell effector function by preventing LAG-3 from binding to its primary ligand, major histocompatibility complex (MHC) class II molecules. Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response. The combination of Favezelimab and Pembrolizumab is currently being evaluated in the Phase III KEYFORM-007 trial for colorectal cancer.
- LUMAKRAS (sotorasib): Amgen
LUMAKRAS is a KRASG12C small molecule inhibitor under investigation for the treatment of advanced colorectal cancer. LUMAKRAS is being investigated in previously treated KRAS G12C-mutated CRC in combination with other therapies. In August 2023, Amgen announced that the US Food and Drug Administration (FDA), granted Breakthrough Therapy Designation to LUMAKRAS.
Discover key developments and opportunities in the Colorectal Cancer Market. Click here to learn more from DelveInsight’s latest report @ Colorectal Cancer Market Size
Colorectal Cancer Drugs Market Insights
- KRAS inhibitors
KRAS inhibitors are a class of targeted therapies designed to inhibit the activity of the KRAS protein, which is often mutated in various cancers, including colorectal cancer. These mutations lead to uncontrolled cell growth and cancer progression. KRAS inhibitors specifically target the mutated form of the KRAS protein, particularly the G12C mutation. By binding to this mutant protein, they lock it in an inactive state, preventing it from sending growth signals to the cancer cells. These inhibitors are used in patients with specific KRAS mutations and have shown effectiveness in shrinking tumors and delaying disease progression. They are often used when other treatments have failed.
- HER2 inhibitors
HER2 inhibitors are targeted therapies used to treat cancers that overexpress the HER2 protein, such as certain types of breast cancer. HER2 (human epidermal growth factor receptor 2) is a protein that promotes cell growth, and its overexpression can lead to aggressive cancer behavior. HER2 inhibitors work by blocking the HER2 receptors on cancer cells, preventing them from receiving growth signals. This can slow or stop the growth of HER2-positive cancer cells.
Colorectal Cancer Market Outlook
The colorectal cancer therapeutics market is expected to grow at a CAGR of ~5% through 2034, driven by an aging population, increased screening, and innovative treatments. Key trends include the rise of targeted therapies, such as KRAS inhibitors, and advancements in immunotherapy, including checkpoint inhibitors and CAR-T therapies. Early detection methods, such as liquid biopsies and genetic screening, are enhancing diagnosis and shifting treatment approaches. The competitive landscape features major Colorectal cancer companies like Pfizer, Merck, and Roche, though high costs and tumor resistance present challenges. Opportunities lie in emerging markets and personalized medicine, promising growth and improved patient outcomes.
Download DelveInsight’s Colorectal Cancer Market report today and stay ahead in this rapidly evolving field. @ Colorectal Cancer Clinical Trials
Scope of the Colorectal Cancer Market Report
- Coverage- 7MM
- Study Period- 2020-2034
- Colorectal Cancer Companies- Shanghai Henlius Biotech, Agenus, Tizona Therapeutics, Surgimab, Novartis, Bexion Pharmaceuticals, Syndax Pharmaceuticals, Exelixis, AbbVie, Tyligand Pharmaceuticals, Bristol Myers Squibb, Eisai, Bold Therapeutics, and others.
- Colorectal Cancer Therapies-Serplulimab（HLX10) + Bevacizumab + Chemotherapy, Botensilimab ± Balstilimab, TTX-080, SGM-101, HRO761, BXQ-350 + FOLFOX + bevacizumab, Revumenib, Zanzalintinib + atezolizumab vs. regorafenib, Temab-A (ABBV-400), TSN333 and TSN1611, Pumitamig, E7386, BOLD-100 in combination with FOLFOX Chemotherapy, and others.
- Colorectal Cancer Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Colorectal Cancer Unmet Needs, KOL’s views, Analyst’s views, Colorectal Cancer Market Access and Reimbursement
Table of Contents
1. Key Insights
2. Colorectal Cancer Market Report Introduction
3. Country-wise Colorectal Cancer Market Overview at a Glance
4. Colorectal Cancer Market Overview by Therapeutic Class
5. Methodology of Colorectal Cancer Epidemiology and Market
6. Colorectal Cancer Executive Summary
7. Key Events
8. Colorectal Cancer Disease Background and Overview
9. Colorectal Cancer Epidemiology and Patient Population
10. Colorectal Cancer Patient Journey
11. Colorectal Cancer Marketed Drugs
12. Colorectal Cancer Emerging Drugs
13. Colorectal Cancer: Market Analysis
14. Key Opinion Leaders’ Views
15. Colorectal Cancer SWOT Analysis
16. Colorectal Cancer Unmet Needs
17. Colorectal Cancer Market Access and Reimbursement
18. Appendix
19. Colorectal Cancer Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
